Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 11/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | PGK2 | P07205 | 1/20 | 0.37 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11327768 | 0.88 | FDPS (0.70) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL5054852 | 0.83 | FDPS (0.67) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL8825784 | 0.82 | FDPS (0.77) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL4104675 | 0.82 | FDPS (0.73) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL5490591 | 0.81 | FDPS (0.68) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL12797880 | 0.81 | FDPS (0.56) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL1285892 | 0.80 | FDPS (0.61) | FDPSPDE3ALMNAADRB3PDE4D | |
| Water SCHEMBL5162288 | 0.80 | FDPS (0.70) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL13308413 | 0.78 | FDPS (0.54) | FDPSPDE3ALMNAADRB3PDE4D | |
| SCHEMBL4106973 | 0.78 | FDPS (0.58) | FDPSPDE3ALMNAADRB3PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0753523-A1 | Amino-substituted bisphosphonic acids | GADOR S.A. (AR) | 1997-01-15 | — | — | EP | claimed |
| US-8853187-B2 | Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof | GADOR S.A. (AR) | 2014-10-07 | — | — | US | disclosed |
| US-8293029-B2 | Colored conversion layers on metal surfaces | HENKEL AG & CO. KGAA (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20090247491-A1 | COMPOSITION COMPRISING BISPHOSPHONATES FOR PREVENTION AND/OR TREATMENT OF METABOLIC DISEASES OF BONES, PROCESS FOR PREPARING SUCH COMPOSITION AND USE THEREOF | GADOR S.A. (AR) | 2009-10-01 | — | — | US | disclosed |
| US-7560490-B2 | A bisphosphonate, carboxymethyl cellulose and xanthan gum viscosity agents, flavorants and purified water | GADOR S.A. (AR) | 2009-07-14 | — | — | US | disclosed |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
| EP-1658392-B1 | COLOUR CONVERSION LAYERS ON METAL SURFACES | HENKEL KGAA (DE) | 2007-03-14 | — | — | EP | disclosed |
| US-20060173099-A1 | Colored conversion layers on metal surfaces | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-08-03 | — | — | US | disclosed |
| US-6670399-B2 | Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-12-30 | — | — | US | disclosed |
| EP-0837682-B1 | THERAPEUTIC USE OF 1-AMINO-3-(N,N-DIMETHYLAMINO)-PROPYLIDEN-1,1-BISPHOSPHONIC ACID AND ITS SALTS | GADOR SA (AR) | 2002-11-06 | — | — | EP | disclosed |
| US-5990098-A | AS BIOLOGICAL CARRIER FOR A BONE ACTIVE SUBSTANCE SUCH AS CYTOKINES, GROWTHS FACTORS, PROSTAGLANDINS, HORMONES AND CYTOSTATIC DRUGS; TREATING BONE OR MINERAL METABOLIC DISORDERS SUCH AS OSTEOPOROSIS, ARTHRITIS | GADOR, S.A. (AR) | 1999-11-23 | — | — | US | disclosed |
| EP-0837682-A1 | THERAPEUTIC USE OF 1-AMINO-3-(N,N-DIMETHYLAMINO)-PROPYLIDEN-1,1-BISPHOSPHONIC ACID AND ITS SALTS | GADOR S.A. (AR) | 1998-04-29 | — | — | EP | disclosed |
| WO-1997002827-A1 | THERAPEUTIC USE OF 1-AMINO-3-(N,N-DIMETHYLAMINO)-PROPYLIDEN-1,1-BISPHOSPHONIC ACID AND ITS SALTS | GADOR S.A. (AR) | 1997-01-30 | — | — | WO | disclosed |
| EP-0753523-A1 | Amino-substituted bisphosphonic acids | GADOR S.A. (AR) | 1997-01-15 | — | — | EP | disclosed |
| EP-0001584-B1 | HYDROXYDIPHOSPHONIC ACIDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS COMPLEX-FORMING AGENTS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1982-06-30 | — | — | EP | disclosed |
| US-4267108-A | USEFUL AS STABILIZERS, SEQUESTERING AGENTS, ANTIDEPOSIT AGENTS, ANTISCALING AGENTS AND PHARMACEUTICALS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1981-05-12 | — | — | US | disclosed |
| EP-0001584-A1 | Hydroxydiphosphonic acids, process for their preparation and their use as complex-forming agents | Henkel Kommanditgesellschaft auf Aktien (DE) | 1979-05-02 | — | — | EP | disclosed |
| US-4064164-A | SEQUESTERING AGENTS, ANTICARIES AGENTS, CALCIUM OR PHOSPHATE METABOLISM ABNORMALITIES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DT) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247491-A1 | COMPOSITION COMPRISING BISPHOSPHONATES FOR PREVENTION AND/OR TREATMENT OF METABOLIC DISEASES OF BONES, PROCESS FOR PREPARING SUCH COMPOSITION AND USE THEREOF | SOST, BPGM, FBP1 | FDPS 84/4885PDE3A 610/4885LMNA 763/4885 |
| US-20080317834-A1 | Compounds and methods for modulating cerebral amyloid angiopathy | APP, PYGB, MAPT | FDPS 1920/4885PDE3A 685/4885LMNA 1103/4885 |
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | FDPS 4229/4885PDE3A 2085/4885LMNA 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.